CN114886921A - Novel stem cell preparation and application thereof in treating cerebral hemorrhage - Google Patents
Novel stem cell preparation and application thereof in treating cerebral hemorrhage Download PDFInfo
- Publication number
- CN114886921A CN114886921A CN202210518095.0A CN202210518095A CN114886921A CN 114886921 A CN114886921 A CN 114886921A CN 202210518095 A CN202210518095 A CN 202210518095A CN 114886921 A CN114886921 A CN 114886921A
- Authority
- CN
- China
- Prior art keywords
- cerebral hemorrhage
- treatment
- stem cell
- cell preparation
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010008111 Cerebral haemorrhage Diseases 0.000 title claims abstract description 30
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 14
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 9
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims abstract description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims abstract description 4
- 230000001464 adherent effect Effects 0.000 claims abstract description 4
- 210000004369 blood Anatomy 0.000 claims abstract description 4
- 239000008280 blood Substances 0.000 claims abstract description 4
- 238000012258 culturing Methods 0.000 claims abstract description 4
- 238000000432 density-gradient centrifugation Methods 0.000 claims abstract description 4
- 239000012091 fetal bovine serum Substances 0.000 claims abstract description 4
- 238000000684 flow cytometry Methods 0.000 claims abstract description 4
- 206010018852 Haematoma Diseases 0.000 claims description 16
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 206010030113 Oedema Diseases 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000007428 craniotomy Methods 0.000 claims description 3
- 238000005553 drilling Methods 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 230000007971 neurological deficit Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000002636 symptomatic treatment Methods 0.000 claims description 3
- 208000030218 transient fever Diseases 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 9
- 208000028389 Nerve injury Diseases 0.000 abstract description 4
- 230000008764 nerve damage Effects 0.000 abstract description 4
- 238000004393 prognosis Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract 1
- 230000006378 damage Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000011476 stem cell transplantation Methods 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 206010048962 Brain oedema Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a novel stem cell preparation and application thereof in treating cerebral hemorrhage, which comprises the following steps: collecting healthy adult bone marrow blood, and culturing by density gradient centrifugation combined with adherence to obtain purified MSC S Continuous culture and expansion of MSCs using low-sugar DMEM containing 10% fetal bovine serum S (ii) a Detecting cell CD by observing cell morphology and adherent growth characteristics by using flow cytometry 29 、CD 34 、CD 45 And identifying the cultured MSCS. The traditional Chinese medicine composition shows good treatment effect on the aspect of repairing nerve injury after cerebral hemorrhage, radically changes the prognosis of patients with cerebral hemorrhage, and improves the quality of life of the patients.
Description
Technical Field
The invention relates to the field of medical treatment, in particular to a novel stem cell preparation and application thereof in treating cerebral hemorrhage.
Background
Cerebral hemorrhage is a more violent neurological emergency with severe neurological impairment caused by hematoma formed after intracranial vascular rupture. The early stage of cerebral hemorrhage is mainly caused by mechanical injury to brain tissue due to the compression and space occupying effects of hematoma, and secondary injury at the later stage of hemorrhage can also cause serious damage to nerve tissue structures and functions to different degrees, and the factors together cause that the traditional medicine and operation treatment effect is not ideal at present. Due to its complex pathological changes including neuronal loss, infiltration of inflammatory cells and scar formation of glial fibers, the clinical prognosis of patients is very poor, and it puts heavy pressure and economic burden on families and society.
After cerebral hemorrhage occurs, the injury around the hemorrhage focus involves multiple levels and links, including the space occupying effect of hematoma, inflammatory reaction, free radical injury, and the like. Initial bleeding can destroy the physical structure of brain tissue, and the formation and expansion of hematoma can also stress normal brain tissue, causing primary damage. Inflammation, erythrocyte lysis, thrombin generation and the like can cause secondary brain injury such as cerebral edema, blood brain barrier damage, nerve tissue necrosis and the like, and further cause the continuous deterioration of nerve function. With the increasing awareness of inflammatory responses to cerebral hemorrhage, inflammatory responses are considered to be the most critical factor in secondary damage after cerebral hemorrhage. A plurality of researches show that the intervention treatment for inhibiting inflammatory reaction can reduce the mass expression of inflammatory factors after cerebral hemorrhage, relieve cerebral edema and obviously improve the nerve function damage. Therefore, anti-inflammatory treatment of inflammatory responses after cerebral hemorrhage has attracted general attention.
With the intensive research on mesenchymal stem cells, mesenchymal stem cells have been widely used in clinical practice as a means for treating and repairing irreversible brain damage caused by cerebrovascular diseases. The mesenchymal stem cells used in clinic at present are mainly derived from bone marrow, umbilical cord and umbilical cord blood. The stem cells are classified into autologous cells and allogeneic stem cells according to different sources.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a novel stem cell preparation and application thereof in treating cerebral hemorrhage, which show good treatment effect in the aspect of repairing nerve injury after cerebral hemorrhage, radically change the prognosis of patients with cerebral hemorrhage and improve the survival quality of the patients.
In order to achieve the aim of the invention, the invention adopts the specific scheme that:
a novel stem cell preparation and its use for treating cerebral hemorrhage, comprising: human bone marrowCollecting bone marrow blood of healthy adult, and culturing by density gradient centrifugation combined with adherence to obtain purified MSC S Continuous culture and expansion of MSCs using low-sugar DMEM containing 10% fetal bovine serum S (ii) a Detecting cell CD by observing cell morphology and adherent growth characteristics by using flow cytometry 29 、CD 34 、CD 45 And identifying the cultured MSCS.
Furthermore, 37 patients with cerebral hemorrhage treated by mesenchymal thousand cells are researched, the patients are treated by adopting a drilling drainage method or a craniotomy hematoma removal method, and a drainage tube is reserved and retreated to the edge of a hematoma cavity in the treatment process.
Furthermore, a drainage tube injection method is adopted for autologous mesenchymal stem cells to be transplanted for treatment; and the degree of neurological deficit (NIHSS score) before and after treatment was assessed.
Furthermore, by comparing the NIHSS scores of the study population before and after mesenchymal stem cell transplantation, the NIHSS score of the patient is obviously reduced (P is less than 0.05) after 6 months of treatment, and the hematoma volume and the edema volume of the patient are obviously reduced (P is less than 0.05) before and after the treatment; some patients have a transient fever reaction, and the fever disappears after symptomatic treatment.
The invention has the beneficial effects that:
the materials are easy to obtain, and the cells can be obtained by bone marrow puncture, so that immunological rejection and ethical disputes are avoided; the culture proliferation speed is high, and a large amount of amplification can be realized in a short period, so that the culture medium is more suitable for clinical treatment. The treatment effect of bone marrow mesenchymal stem cell transplantation on nervous system injury is proved in different clinical researches, and the action mechanism is multifaceted; can pass through the blood brain barrier; no immunological rejection was observed in either allografts or xenotransplants. The method has the advantages that the autologous mesenchymal stem cell transplantation is adopted to provide an effective method for treating the nerve injury after cerebral hemorrhage, and along with the development of research foundation and clinical practice of mesenchymal stem cells, the autologous bone marrow mesenchymal stem cell transplantation is used as a safe and comprehensive method with less side effect, and the good treatment effect is shown in the aspect of repairing the nerve injury after cerebral hemorrhage, so that the prognosis of a cerebral hemorrhage patient is fundamentally changed, and the survival quality of the patient is improved.
Detailed Description
The present invention is further described below by way of specific examples, but the present invention is not limited to only the following examples. Variations, combinations, or substitutions of the invention, which are within the scope of the invention or the spirit, scope of the invention, will be apparent to those of skill in the art and are within the scope of the invention.
A novel stem cell preparation and its use for treating cerebral hemorrhage, comprising: collecting healthy adult bone marrow blood, and culturing by density gradient centrifugation combined with adherence to obtain purified MSC S Continuous culture and expansion of MSCs using low-sugar DMEM containing 10% fetal bovine serum S (ii) a Detecting cell CD by observing cell morphology and adherent growth characteristics by using flow cytometry 29 、CD 34 、CD 45 And identifying the cultured MSCS.
37 patients who adopt mesenchymal thousand cells to treat cerebral hemorrhage are researched, the patients are treated by adopting a method of drilling drainage or craniotomy hematoma removal, and a drainage tube is reserved and retreated to the edge of a hematoma cavity in the treatment process. Adopting a drainage tube injection method to carry out autologous bone marrow mesenchymal cell transplantation treatment; and the degree of neurological deficit (NIHSS score) before and after treatment was assessed. By comparing the NIHSS scores before and after the transplantation of the mesenchymal stem cells of the study population, the NIHSS score of the patient is obviously reduced (P is less than 0.05) after 6 months of treatment, and the hematoma volume and the edema volume of the patient are obviously reduced (P is less than 0.05) before and after the treatment; some patients have a transient fever reaction, and the fever disappears after symptomatic treatment.
37 patients with cerebral hemorrhage treated by mesenchymal stem cells are taken as research objects, wherein 18 men and 19 women meet the diagnosis standard established by the fourth cerebrovascular disease academic conference, and all patients have cerebral hemorrhage confirmed by skull C T and have short course of disease.
Analyzing the neurological impairment degree and daily life and activity ability before and after treatment of the population: the NIHSS scores before and after treatment are respectively (20.22 +/-5.94) and (11.05 +/-5.47), and the comparison of the NIHSS scores before and after treatment of the study population shows that the score after treatment is obviously lower than the level before treatment (P < 0.05). Analysis of hematoma volume and edema volume before and after treatment for study population: comparison of hematoma and edema volumes before and after treatment in the study population showed a significant decrease in both hematoma and edema volumes (P <0.05) in the patients after treatment compared to before treatment. See table 1 for details:
the above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the present invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (4)
1. A novel stem cell preparation and its use for treating cerebral hemorrhage, comprising: collecting healthy adult bone marrow blood, and culturing by density gradient centrifugation combined with adherence to obtain purified MSC S Continuous culture and expansion of MSCs using low-sugar DMEM containing 10% fetal bovine serum S (ii) a Detecting cell CD by observing cell morphology and adherent growth characteristics by using flow cytometry 29 、CD 34 、CD 45 And identifying the cultured MSCS.
2. The novel stem cell preparation and the use thereof for treating cerebral hemorrhage according to claim 1, wherein 37 patients with cerebral hemorrhage treated by mesenchymal stem cells are studied, and are treated by drilling drainage or craniotomy for hematoma removal, and a drainage tube is left and is retracted to the edge of a hematoma cavity in the treatment process.
3. The novel stem cell preparation and the use thereof for treating cerebral hemorrhage according to claim 2, wherein autologous mesenchymal stem cells are subjected to cell transplantation treatment by using a drainage tube injection method; and the degree of neurological deficit (NIHSS score) before and after treatment was assessed.
4. The novel stem cell preparation and the use thereof for treating cerebral hemorrhage according to claim 3, wherein the NIHSS score of the patient after 6 months of treatment is obviously reduced (P <0.05), and the hematoma volume and the edema volume of the patient before and after treatment are obviously reduced (P <0.05) by comparing the NIHSS score before and after the transplantation of the mesenchymal stem cells of the study population; some patients have a transient fever reaction, and the fever disappears after symptomatic treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210518095.0A CN114886921A (en) | 2022-05-13 | 2022-05-13 | Novel stem cell preparation and application thereof in treating cerebral hemorrhage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210518095.0A CN114886921A (en) | 2022-05-13 | 2022-05-13 | Novel stem cell preparation and application thereof in treating cerebral hemorrhage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114886921A true CN114886921A (en) | 2022-08-12 |
Family
ID=82722057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210518095.0A Pending CN114886921A (en) | 2022-05-13 | 2022-05-13 | Novel stem cell preparation and application thereof in treating cerebral hemorrhage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114886921A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1803193A (en) * | 2005-01-13 | 2006-07-19 | 中山大学 | Use of stroma stem cell derived from bone marrow in preparing formulation for treating hypoxic ischemic cerebral palsy |
| CN103773734A (en) * | 2014-01-24 | 2014-05-07 | 浙江大学 | Preparation method of tissue engineering cell sheet with osteogenic differentiation and vasculogenesis |
| CN104546916A (en) * | 2015-02-06 | 2015-04-29 | 吉林省拓华生物科技有限公司 | Novel stem cell preparation and application thereof in treating cerebral hemorrhage |
| CN105838673A (en) * | 2016-06-07 | 2016-08-10 | 三峡大学仁和医院 | Extraction and separation method for mesenchymal stem cells (MSCs) |
| CN113412118A (en) * | 2019-02-07 | 2021-09-17 | 北海道公立大学法人札幌医科大学 | Pharmaceutical composition for preventing in-stent restenosis |
-
2022
- 2022-05-13 CN CN202210518095.0A patent/CN114886921A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1803193A (en) * | 2005-01-13 | 2006-07-19 | 中山大学 | Use of stroma stem cell derived from bone marrow in preparing formulation for treating hypoxic ischemic cerebral palsy |
| CN103773734A (en) * | 2014-01-24 | 2014-05-07 | 浙江大学 | Preparation method of tissue engineering cell sheet with osteogenic differentiation and vasculogenesis |
| CN104546916A (en) * | 2015-02-06 | 2015-04-29 | 吉林省拓华生物科技有限公司 | Novel stem cell preparation and application thereof in treating cerebral hemorrhage |
| CN105838673A (en) * | 2016-06-07 | 2016-08-10 | 三峡大学仁和医院 | Extraction and separation method for mesenchymal stem cells (MSCs) |
| CN113412118A (en) * | 2019-02-07 | 2021-09-17 | 北海道公立大学法人札幌医科大学 | Pharmaceutical composition for preventing in-stent restenosis |
Non-Patent Citations (1)
| Title |
|---|
| PENG HUANG ET AL: "safety and efficacy of intraventricular delivery of bone marrow-derived mesenchymal stem cells in hemorrhagic stroke model", SCIENTIFIC REPORTS, no. 9, 5 April 2019 (2019-04-05), pages 1 - 9 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lodi et al. | Stem cells in clinical practice: applications and warnings | |
| US9211306B2 (en) | Cellular therapeutic agent for incontinence or urine comprising stem cells originated from decidua or adipose | |
| US20230227786A1 (en) | PREPARATION METHOD AND RECOVERY METHOD OF PARIDUVAL MESENCHYMAL STEM CELLS (PMSCs) | |
| CN113444684B (en) | Method for preparing stem cell apoptosis body for repairing endometrium and improving fertility | |
| EP1929006A1 (en) | Activating agent of stem cells and/or progenitor cells | |
| CN114886921A (en) | Novel stem cell preparation and application thereof in treating cerebral hemorrhage | |
| JP7536848B2 (en) | Urine-derived mesenchymal stem cell mitochondria and transplantation method and use thereof | |
| CN116496980A (en) | Intestinal crypt separating liquid for inflammatory bowel disease, separating method and in-vitro 3D organoid culture method | |
| CN115212232A (en) | Methods and compositions for treating stroke with mesenchymal stem cell-derived exosomes | |
| WO2021011779A2 (en) | Mesenchymal stem cell compositions | |
| CN111662864A (en) | Method for differentiating umbilical cord mesenchymal stem cells into dermal stem cells through in-vitro induction | |
| WO2022199632A1 (en) | Stem cell drug for treating atherosclerosis | |
| KR101423659B1 (en) | Composition Comprising Pre-differentiated Amniotic Fluid Stem Cells for Treating Urinary Incontinence | |
| CN113679741B (en) | Application of human amniotic epithelial stem cells in preparation of medicines for treating cisplatin-induced acute kidney injury | |
| CN111454897B (en) | Domestication method for improving adaptation of mesenchymal stem cells to high-sugar environment and application of domestication method | |
| CN114836381B (en) | Method for inducing directional differentiation of mesenchymal stem cells into nerve cells and culture medium thereof | |
| CN118853551A (en) | Preparation and culture method of autologous bone marrow mesenchymal stem cells for treating cerebrovascular diseases | |
| CN108060116B (en) | Extraction, separation and culture method of fetal rat endothelial progenitor cells | |
| Nguyen et al. | SAFETY AND EFFICACY OF STEM CELL THERAPY FOR TREATMENT SEVERE TRAUMATIC BRAIN INJURY | |
| CN115261313A (en) | Preparation method and application of exosome derived from human placenta mesenchymal stem cells | |
| CN117025506A (en) | Biological agent containing kidney precursor-like cells, preparation method and application thereof | |
| Tsai et al. | MP44-16 MICRODISSECTION TESTICULAR SPERM EXTRACTION FOR NON-OBSTRUCTIVE AZOOSPERMIA-IS LONGITUDINAL TESTICULAR INCISION BETTER? | |
| Pang et al. | Clinical Study of Microscopical Operation through Lateral Fissure Approach for Hypertensive Intracerebral Hemorrhage. | |
| CN116121183A (en) | Application of M4 complete culture medium in culture of mesenchymal stem cells of uterine blood | |
| CN117535236A (en) | Culture method for promoting symmetrical division of umbilical cord mesenchymal stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |